Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Watanabe

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 1, 1996
Pharmacotherapy of depression: focused considerations for primary careT Hartman, M D Watanabe
Psychiatric Medicine|January 1, 1991
Atypical antipsychoticsD Holland, M D Watanabe, R Sharma
Molecular Pharmacology|February 1, 1987
Free radical pathways in the in vitro hepatic metabolism of phenelzineP R Ortiz de Montellano, M D Watanabe
Clinical Pharmacy|September 1, 1990
Pathophysiologic basis for schizophrenia and the efficacy of antipsychoticsL Ereshefsky, T K Tran-Johnson, M D Watanabe
Clinical Pharmacy|October 1, 1989
Clozapine: an atypical antipsychotic agentL Ereshefsky, M D Watanabe, T K Tran-Johnson
Journal of Clinical Psychopharmacology|October 1, 1991
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variablesL Ereshefsky, S R Saklad, M D Watanabe, et al.
Drugs|May 1, 1994
Depot antipsychotic drugs. Place in therapyJ M Davis, L Matalon, M D Watanabe, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|January 1, 1995
Successful methylphenidate treatment of apathy after subcortical infarctsM D Watanabe, E M Martin, O A DeLeon, et al.
Neuropsychobiology|January 1, 1997
Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptomsR P Sharma, L E Shapiro, S K Kamath, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 1, 1996
Pharmacotherapy of depression: focused considerations for primary careT Hartman, M D Watanabe
Psychiatric Medicine|January 1, 1991
Atypical antipsychoticsD Holland, M D Watanabe, R Sharma
Molecular Pharmacology|February 1, 1987
Free radical pathways in the in vitro hepatic metabolism of phenelzineP R Ortiz de Montellano, M D Watanabe
Clinical Pharmacy|September 1, 1990
Pathophysiologic basis for schizophrenia and the efficacy of antipsychoticsL Ereshefsky, T K Tran-Johnson, M D Watanabe
Clinical Pharmacy|October 1, 1989
Clozapine: an atypical antipsychotic agentL Ereshefsky, M D Watanabe, T K Tran-Johnson
Journal of Clinical Psychopharmacology|October 1, 1991
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variablesL Ereshefsky, S R Saklad, M D Watanabe, et al.
Drugs|May 1, 1994
Depot antipsychotic drugs. Place in therapyJ M Davis, L Matalon, M D Watanabe, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|January 1, 1995
Successful methylphenidate treatment of apathy after subcortical infarctsM D Watanabe, E M Martin, O A DeLeon, et al.
Neuropsychobiology|January 1, 1997
Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptomsR P Sharma, L E Shapiro, S K Kamath, et al.
Pageof 1